Literature DB >> 10693552

Minor column structural acetabular allografts in revision hip arthroplasty.

I G Woodgate1, K J Saleh, G Jaroszynski, Z Agnidis, M M Woodgate, A E Gross.   

Abstract

A minor column (shelf) allograft is used for uncontained defects that involve less than 50% of the acetabulum. The prospectively collected records and radiographs of 47 patients (51 hips) who had undergone minor column structural acetabular allograft reconstruction during revision hip arthroplasty were reviewed. The purpose was to identify the long-term results (minimum 5 years) and factors that may influence longevity of the allograft and predispose the patient to subsequent acetabular component failure. The mean duration of followup was 119 months (range, 68-195 months). There was one perioperative death and six patients were lost to followup. Eleven patients (22%) required additional surgery. Three acetabular cups could not be revised successfully, despite multiple attempts, and the patients were treated with Girdlestone excisions. Eight patients underwent successful revision surgery with only three requiring a repeat structural allograft. Survival time for the acetabular cup as determined by Kaplan-Meier analysis was 153 months (95% confidence interval; range, 136-169 months). Cup failure was associated with more operative procedures performed before revision surgery (mean, 3.2 procedures), and failure to restore the vertical center of hip rotation to within 12 to 14 mm of the predicted value. The acetabular abduction angle was not a predictor for failure. The current study shows that good results can be achieved with structural acetabular allograft reconstruction with mid-term to long-term implant survival (cup aseptic survival, 80.4% and allograft re-construction survival, 94.1%), especially if there is restoration of near normal hip biomechanics.

Entities:  

Mesh:

Year:  2000        PMID: 10693552     DOI: 10.1097/00003086-200002000-00009

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  8 in total

1.  Long-term results for minor column allografts in revision hip arthroplasty.

Authors:  Paul T H Lee; Guy Raz; Oleg A Safir; David J Backstein; Allan E Gross
Journal:  Clin Orthop Relat Res       Date:  2010-12       Impact factor: 4.176

2.  Structural allograft and primary press-fit cup for severe acetabular deficiency. A minimum 6-year follow-up study.

Authors:  F Traina; F Giardina; M De Clerico; A Toni
Journal:  Int Orthop       Date:  2005-04-05       Impact factor: 3.075

3.  CT Lesion Model-Based Structural Allografts: Custom Fabrication and Clinical Experience.

Authors:  Jan Claas Brune; Uwe Hesselbarth; Philipp Seifert; Dimitri Nowack; Rüdiger von Versen; Mark David Smith; Dirk Seifert
Journal:  Transfus Med Hemother       Date:  2012-11-13       Impact factor: 3.747

4.  Continued good results with modular trabecular metal augments for acetabular defects in hip arthroplasty at 7 to 11 years.

Authors:  Michael R Whitehouse; Bassam A Masri; Clive P Duncan; Donald S Garbuz
Journal:  Clin Orthop Relat Res       Date:  2015-02       Impact factor: 4.176

5.  Structural allograft as an option for treating infected hip arthroplasty with massive bone loss.

Authors:  Paul T H Lee; Robert A Clayton; Oleg A Safir; David J Backstein; Allan E Gross
Journal:  Clin Orthop Relat Res       Date:  2011-04       Impact factor: 4.176

6.  Tantalum augments for Paprosky IIIA defects remain stable at midterm followup.

Authors:  Daniel J Del Gaizo; Vamsi Kancherla; Scott M Sporer; Wayne G Paprosky
Journal:  Clin Orthop Relat Res       Date:  2012-02       Impact factor: 4.176

Review 7.  Bone grafts, bone graft extenders, substitutes and enhancers for acetabular reconstruction in revision total hip arthroplasty.

Authors:  Luca Pierannunzii; Luigi Zagra
Journal:  EFORT Open Rev       Date:  2017-03-13

8.  Total revision of the hip using allograft to correct particle disease induced osteolysis: a case study.

Authors:  Drew W Taylor; Jennifer E Taylor; Igal Raizman; Allan E Gross
Journal:  Mcgill J Med       Date:  2009-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.